Definitive Contract HHSN261200511010C
Award Date 1/15/05
Potential Completion Date 1/14/10
Potential Value $20M
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Houston, TX 77030, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
15
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a federal contract award by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to The University of Texas M.D. Anderson Cancer Center (MD Anderson) to provide additional funding for a previously awarded contract, 263-MJ-611300. The contract is a firm-fixed-price purchase order with a ceiling value of $100,000.00 and an ultimate completion date of September 30, 2008. The contract does not have a set-aside designation. MD Anderson...
- The National Cancer Institute (NCI) awarded a $2,067,521.23 delivery order contract to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct early phase clinical research for the Cancer Prevention Agent Development Program. This contract is a child under the larger Cancer Prevention Agent Development Program 2012-2017 indefinite delivery vehicle. MD Anderson, as a comprehensive cancer research and treatment center, will provide various services in support of this cancer...
- This is a firm fixed price delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson) in the amount of $400,411.43. The contract was issued under the PREVENT Cancer Program (PREVENT) contract vehicle and supports the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS project with a period of performance through...
- This is a three-year, $13,481,325.00 definitive contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract supports a Phase II chemoprevention clinical trial in patients with adenomatous polyposis coli, a genetic condition that increases cancer risk. The contract does not have a small business set-aside designation. MD Anderson Cancer Center, a comprehensive cancer research and...
- This is a federal contract award made by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson), a component of the University of Texas System. The award, valued at $2,387,945.37, is for biomedical research and development activities, with an ultimate completion date of August 21, 2013. The contract is a definitive contract with a cost-no-fee pricing type, and does not have...
- This is a prime contract awarded by the U.S. government to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is for $6,155,674.00 and is a Definitive Contract with Cost No Fee pricing. The place of performance is Texas, USA. The contract is for biomedical (applied/exploratory) services and does not have a set-aside designation. MD Anderson Cancer Center, a comprehensive cancer treatment and research center, has received this prime...
- This federal contract award, valued at $1,272,481.00, was issued by the National Cancer Institute to The University of Texas M.D. Anderson Cancer Center, a child entity of the University of Texas System. The contract is part of the "PREVENT Preclinical Drug Development Program (PREVENT)" and is focused on "TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCER." It is a firm fixed-price delivery order contract with a completion date of March 14,...
- This is a research and development contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health, to the University of Texas MD Anderson Cancer Center (MD Anderson), a state-controlled higher education institution and comprehensive cancer treatment and research center. The $32,129,968.00 indefinite-delivery, indefinite-quantity (IDIQ) contract, awarded on September 26, 2000, supports the acquisition, testing, transportation, and housing of non-human...
- This is a Delivery Order issued against the National Institutes of Health's PREVENT Cancer Program (PREVENT) Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The award, valued at $4,445.48, was made to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a "CONTRACT ORIENTATION AND KICKOFF MEETING" related to the PRECLINICAL PREVENT CANCER PROGRAM initiative. The award has an ultimate completion date of December 31, 2015 and does...
- This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is part of the PREVENT Cancer Program, a preclinical research initiative focused on developing prevention strategies for breast cancer. The $714,123.60 contract supports "TARGETING THE MTOR PATHWAY FOR THE PREVENTION OF...